Immunoprofiling HTLV-1 Blood Samples Show Altered Innate Cell Responsiveness
|
By LabMedica International staff writers Posted on 09 Dec 2021 |

Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Bioscience)
The Human T-cell Leukemia Virus-1 (HTLV-1)-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is a progressive neurodegenerative disease characterized by the demyelination of the middle-to-lower thoracic cord.
HTLV-1 targets mainly T-cells, altering their function and ability to induce an antiviral specific immune response, even participating in the disease evolution as mentioned previously. However, in addition to T-cells, HTLV-1 also targets innate immune cells such as classical and plasmacytoid dendritic cells (cDCs and pDCs, respectively), as well as monocytes.
Medical Virologists at the Université Claude Bernard Lyon 1 (Lyon, France) and their colleagues analyzed innate cell responses at steady state and after blood cell stimulation using an agonist of the toll-like receptor (TLR)7/8-signaling pathway in blood samples from a Brazilian cohort (15 HAM/TSP patients, 15 HTLV-1 asymptomatic carriers, and 15 non-infected individuals). The average age was 52 ±6.35 years for men and 49.15 ±10.84 years for women. Age means were 49.8 years for healthy donors (HD), 46.93 years for asymptomatic carriers (AC) and 53.8 years for HAM/TSP.
HTLV-1 serologic diagnosis was made by ELISA (Ortho Diagnostics, Rochester, NY, USA) and positive samples were confirmed by western blot. All patients whose serum sample was reactive with either test was submitted to a nested-PCR using HTLV-1 generic primers and amplified products were digested with restriction enzymes. Blood samples were processed, stimulated and analyzed with a LSR Fortessa X-20 cytometer (BD Biosciences, San Jose, CA, USA). Fluorochrome compensation was performed with BD Biosciences’ compensation beads and FMO (Fluorescence Minus One) conditions.
The investigators observed a lower response of IFNα+ DCs and monocytes in HAM/TSP compared to asymptomatic carriers, as a potential consequence of corticosteroid treatments. In contrast, a higher frequency of monocytes producing MIP-1α and pDC producing IL-12 was detected in HAM/TSP blood samples, together with higher IFNγ responsiveness of NK cells, suggesting an increase sensitivity to inflammatory response in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness could be linked or be at the origin of the neuroinflammatory status in HAM/TSP patients.
The authors concluded that their findings suggest an impaired antiviral response and increased inflammatory responsiveness by dendritic cells and monocytes in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness upon innate cell activation could participate in the establishment of the HAM/TSP disease. The study was published on November 12, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Université Claude Bernard Lyon 1
Ortho Diagnostics
BD Bioscience
HTLV-1 targets mainly T-cells, altering their function and ability to induce an antiviral specific immune response, even participating in the disease evolution as mentioned previously. However, in addition to T-cells, HTLV-1 also targets innate immune cells such as classical and plasmacytoid dendritic cells (cDCs and pDCs, respectively), as well as monocytes.
Medical Virologists at the Université Claude Bernard Lyon 1 (Lyon, France) and their colleagues analyzed innate cell responses at steady state and after blood cell stimulation using an agonist of the toll-like receptor (TLR)7/8-signaling pathway in blood samples from a Brazilian cohort (15 HAM/TSP patients, 15 HTLV-1 asymptomatic carriers, and 15 non-infected individuals). The average age was 52 ±6.35 years for men and 49.15 ±10.84 years for women. Age means were 49.8 years for healthy donors (HD), 46.93 years for asymptomatic carriers (AC) and 53.8 years for HAM/TSP.
HTLV-1 serologic diagnosis was made by ELISA (Ortho Diagnostics, Rochester, NY, USA) and positive samples were confirmed by western blot. All patients whose serum sample was reactive with either test was submitted to a nested-PCR using HTLV-1 generic primers and amplified products were digested with restriction enzymes. Blood samples were processed, stimulated and analyzed with a LSR Fortessa X-20 cytometer (BD Biosciences, San Jose, CA, USA). Fluorochrome compensation was performed with BD Biosciences’ compensation beads and FMO (Fluorescence Minus One) conditions.
The investigators observed a lower response of IFNα+ DCs and monocytes in HAM/TSP compared to asymptomatic carriers, as a potential consequence of corticosteroid treatments. In contrast, a higher frequency of monocytes producing MIP-1α and pDC producing IL-12 was detected in HAM/TSP blood samples, together with higher IFNγ responsiveness of NK cells, suggesting an increase sensitivity to inflammatory response in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness could be linked or be at the origin of the neuroinflammatory status in HAM/TSP patients.
The authors concluded that their findings suggest an impaired antiviral response and increased inflammatory responsiveness by dendritic cells and monocytes in HAM/TSP patients compared to asymptomatic carriers. This sustained inflammatory responsiveness upon innate cell activation could participate in the establishment of the HAM/TSP disease. The study was published on November 12, 2021 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Université Claude Bernard Lyon 1
Ortho Diagnostics
BD Bioscience
Latest Immunology News
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
- Novel Tool Uses Deep Learning for Precision Cancer Therapy
- Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients
- Novel Multiplex Assay Supports Diagnosis of Autoimmune Vasculitis
- Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer
- Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read morePathology
view channel
Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
Isolating rare cancer cells from blood is essential for diagnosing metastasis and guiding treatment decisions, but remains technically challenging. Many existing techniques struggle to balance accuracy,... Read moreAI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
Diagnosing blood disorders depends on recognizing subtle abnormalities in cell size, shape, and structure, yet this process is slow, subjective, and requires years of expert training. Even specialists... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








